Phyllis Morgan on Health Disparities in Patients At Risk for Developing Colorectal Cancer

Article

Phyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.

To kick off Colorectal Cancer Awareness month, CancerNetwork® was joined by Phyllis Morgan, PhD, who is an academic coordinator for the Master of Science in Nursing degree program at Walden University, to discuss the most prevalent treatment disparities related to racial and ethnic minorities who are at risk for developing colorectal cancer (CRC).

“We know that African Americans tend to die more from colorectal cancer than other racial groups, with a mortality rate that’s about 40% higher than in other groups,” Morgan said. “Also, they are diagnosed with colorectal cancer more [frequently] than other ethnic groups.”

Morgan went on to say there are different reasons for that, including factors related to detection and screening. To mitigate these challenges, she said education about risk factors, signs and symptoms of the disease, detection methods, as well as treatment modalities are all key areas of need.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content